Bangladesh - engelsk - DGDA (Directorate General of Drug Administration)

novarine pharmaceuticals (unani) - habb-e muqil - capsule

Israel - engelsk - Ministry of Health

novartis israel ltd - everolimus - tablets dispersible - everolimus 2 mg - everolimus - votubia is indicated as adjunctive treatment of patients aged 2 years and older whose refractory epileptic seizures are associated with tuberous sclerosis complex (tsc).

Israel - engelsk - Ministry of Health

novartis israel ltd - everolimus - tablets dispersible - everolimus 3 mg - everolimus - votubia is indicated as adjunctive treatment of patients aged 2 years and older whose refractory epileptic seizures are associated with tuberous sclerosis complex (tsc).

USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - potassium acetate (unii: m911911u02) (potassium cation - unii:295o53k152), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium acetate (unii: 4550k0sc9b) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - potassium acetate 1.96 g in 20 ml - hyperlyte® cr is indicated for use as a supplement to parenteral nutritional solutions containing amino acids, dextrose and/or other calorie sources delivered by central venous or peripheral infusion, to facilitate amino acid utilization and maintain electrolyte balance in adults. hyperlyte® cr (multi-electrolyte concentrate) is also indicated as a source of replacement electrolytes for the depleted adult patient during parenteral therapy. hyperlyte® cr is contraindicated in clinical conditions where the administration of potassium, sodium, calcium, magnesium, or chloride could be clinically detrimental. hyperlyte® cr is not intended for pediatric use.

USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium gluconate (unii: r6q3791s76) (sodium cation - unii:lyr4m0nh37, gluconic acid - unii:r4r8j0q44b), sodium acetate (unii: 4550k0sc9b) (sodium cation - unii:lyr4m0nh37, acetate ion - unii:569dqm74sc), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - uni - sodium chloride 0.53 g in 100 ml - this solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration, and as an alkalinizing agent. this solution is contraindicated where the administration of sodium, potassium, magnesium, chloride, acetate or gluconate could be clinically detrimental.

USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (lactic acid - unii:33x04xa5at), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - dextrose monohydrate 5 g in 100 ml - this solution is indicated for use in adults and pediatric patients as a source of electrolytes, calories and water for hydration. the use of 5% dextrose in lactated ringer’s injection is contraindicated in neonates (28 days of age or younger) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream [see warnings, drug interactions, pediatric use ]. this solution is contraindicated where the administration of sodium, potassium, calcium, chloride or lactate could be clinically detrimental. lactate administration is contraindicated in severe metabolic acidosis or alkalosis, and in severe liver disease or anoxic states which affect lactate metabolism. solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.

USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (lactic acid - unii:33x04xa5at, sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - sodium chloride 0.6 g in 100 ml - this solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. the use of lactated ringer’s injection usp is contraindicated in neonates (28 days of age or younger) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream [see warnings, drug interactions, pediatric use ]. this solution is contraindicated where the administration of sodium, potassium, calcium, lactate, or chloride could be clinically detrimental. lactate administration is contraindicated in severe metabolic acidosis or alkalosis, and in severe liver disease or anoxic states which affect lactate metabolism.

USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (lactic acid - unii:33x04xa5at, sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - this solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. the use of lactated ringer’s injection usp is contraindicated in neonates (28 days of age or younger) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream [see warnings, drug interactions, pediatric use ]. this solution is contraindicated where the administration of sodium, potassium, calcium, lactate, or chloride could be clinically detrimental. lactate administration is contraindicated in severe metabolic acidosis or alkalosis, and in severe liver disease or anoxic states which affect lactate metabolism.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 10mg;  ;   - tablet - 10 mg - active: everolimus 10mg     excipient: butylated hydroxytoluene crospovidone hypromellose lactose lactose monohydrate magnesium stearate - the treatment of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not amenable to surgery. the evidence is based on change in sega volume. further clinical benefit, such as improvement of disease-related symptoms, has not been demonstrated.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 2.5mg;  ;   - tablet - 2.5 mg - active: everolimus 2.5mg     excipient: butylated hydroxytoluene crospovidone hypromellose lactose lactose monohydrate magnesium stearate - the treatment of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not amenable to surgery. the evidence is based on change in sega volume. further clinical benefit, such as improvement of disease-related symptoms, has not been demonstrated.